Increasing Prevalence of Infections in Hospitals Driving HAI Diagnostics Market

The global hospital-acquired infection diagnostics market value is expected to rise from $2,657.6 million in 2016 to $4,386.6 million by 2023, exhibiting a CAGR of 7.6% between 2017 and 2023 (forecast period), as per P&S Intelligence, a market research company based in India. The rising prevalence of infections caused in healthcare settings, such as clinics and hospitals, particularly in emerging countries, due to the poor hygiene in these facilities. 

Besides, the mushrooming population of geriatric people is also expected to fuel the advancement of the HAI diagnostics market. According to the World Population Ageing 2020 report published by the United Nations Department of Economic and Social Affairs (UNDESA), the population of people aged 65 years or above will rise from 727 million in 2020 to more than 1.5 billion by 2050. Moreover, as per the population reference bureau, the total population of Americans aged 65 years and above will rise from 46 million in 2017 to more than 98 million by 2060. 

Depending on test type, the market is divided into urinalysis, immunoassay, and molecular diagnostics. Because of the high incidence of HAIs, such as surgical site infections, urinary tract infections (UTIs), gastrointestinal infections, and bloodstream infections, the immunoassay category contributed the highest revenue to the market in the past, and it is predicted to generate $1,686.2 million revenue in the market by 2023. When product is taken into consideration, the HAI diagnostics market is categorized into reagents & consumables and instruments.

Additionally, the surging prevalence of nosocomial infections is also driving the demand for HAI diagnostic kits in the region. Currently, the major players operating in the HAI diagnostics market, such as Danaher Corporation, AstraZeneca plc, F. Hoffmann-La Roche AG, Bayer AG, Hologic Inc., Daiichi Sankyo Co. Ltd., Johnson & Johnson, and OpGen Inc., are focusing on collaborations in order to strengthen their position in the industry. For example, Abbott Laboratories and Bigfoot Biomedical Inc. entered into an agreement with each other in July 2017 for developing and selling diabetes management systems in North America. 

Hence, the market will boom in the coming years, mainly because of the rising incidence of HAIs and growing public awareness about these infections across the world.